- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04803435
Telemedicine and Face-to-face Consultations Diagnostic Accuracy Comparison in Gastrointestinal Infection Patients
February 10, 2022 updated by: Hospital Israelita Albert Einstein
Telemedicine Evaluation of Immunocompetent Adult Patients With Symptoms Suggestive of Acute Gastrointestinal Infection Compared With Face-to-face Medical Consultation in an Emergency Department: a Randomized Study of Diagnostic Accuracy
Acute gastroenterocolitis (GECA) in healthy adults is a frequent cause of looking for medical care in emergency care units and most cases are aimed at etiology viral infection or food toxin, being generally self-limited with good prognosis and only need for treatment with behavioral measures and use of medications for relief symptomatic.
Anamnesis is the main resource for the diagnosis and stratification of GECA severity and is infrequent alterations of physical examination and complementary examinations without association with symptoms of alert.
Telemedicine has become a resource that allows easier and faster access to medical evaluation, with low cost and rational use of resources.
Virtual emergency care is part of Hospital Israelita Albert Einstein (HIAE) institutional routine and there is a large number of consultations whose final diagnosis was GECA.
It is not known whether the accuracy of diagnosis of GECA by telemedicine is not inferior to the diagnosis by face-to-face evaluation, considered the Golden pattern.
The aim of the study is compare the diagnostic accuracy of GECA by telemedicine with that of face-to-face care.
It is a prospective randomized study with a population of adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious).
Patients whose screening will be excluded of nursing directed for immediate evaluation in the emergency room and patients with dysfunctions organisms or immunosuppression.
Patients who accept and sign the informed consent form will be randomized into 2 groups: A) immediate face-to-face evaluation; B) evaluation initially by telemedicine and sequentially at face-to-face evaluation.
In both cases, the ICD diagnostics will be compiled and grouped according to clinical significance and will be the primary outcome of the study.
Service time, exams requested, guidelines, prescription and destination will also be analyzed.
Patients and doctors who undergoing group B assessment will be blinded to the telemedicine assessment data.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The face-to-face assessment will be carried out by the local UPA medical and assistance team and the assessment by telemedicine by the fixed medical team of the HIAE service responsible for urgency / emergency.
Both in face-to-face evaluation, as well as telemedicine, clinical data, final diagnosis, destination, total time of care, guidance and prescription will be computed.
In the face-to-face evaluation, complementary exams and medications received in situ were computed.
Final diagnoses will receive nomenclature according to the International Statistical Classification of Diseases and Problems Health-Related - ICD 10 (institutional medical record requirement - Cerner) and will be grouped according to equivalence of syndromic diagnosis.
The diagnosis of the face-to-face assessment is made according to protocols based on extensive medical literature and approved by the institutional clinical staff, being representative of current medical practice and will be considered the gold standard diagnosis.
Patients evaluated by telemedicine will be blinded to the diagnosis, recommended destination, guidelines and prescription performed by the medical team.
UPA doctors will be blind to the doctor's assessment telemedicine and telemedicine doctors will not have access to the data obtained in the screening.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age> 18 years
- Symptoms present less than 7 days.
- Without the use of antibiotics in last 30 days prior to the onset of symptoms.
- No trips abroad in the last 15 days prior to the onset of symptoms.
- Presence of more than three episodes of watery diarrhea in the last 24 hours with or without symptoms related to the infection (fever 38oC, chills, sweating, myalgia, vomiting) that motivated / were looking for the Emergency Care Unit
- Signature of informed consent form
Exclusion Criteria:
- Return to the Emergency Care Unit due to maintenance or aggravation of the complaint
- Age> 65 years
- Diagnosis of chronic gastrointestinal diseases, gastritis with or without gastroesophageal reflux disease, previous diverticulitis, previous abdominal surgery, chronic colitis, inflammatory bowel diseases, food intolerances (gluten, lactose)
- Previous diagnosis of congestive heart failure, HIV / AIDS, active cancer, type I diabetes mellitus, use of any immunosuppressant
- Diarrhea chronic
- Patient with emergency room criteria by the nursing evaluation of the triage.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Adult patients with acute gastrointestinal infection - telemedicine before face-to-face evaluation
Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have undergone telemedicine consultation before face-to-face evaluation
|
Direct face-to-face evaluation (without telemedicine consultation before).
Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
|
|
Active Comparator: Adult patients with acute gastrointestinal infection - only face-to-face evaluation
Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have only face-to-face evaluation
|
Direct face-to-face evaluation (without telemedicine consultation before).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of telemedicine diagnosis of adult patients with symptoms compatible with acute gastrointestinal infection
Time Frame: through study completion, an average of 1 year
|
The patient will be evaluated by telemedicine and / or face-to-face consultation and at the end will receive the diagnosis, which will be assigned the ICD code.
At the end, these ICDs will be grouped by the same clinical significance and will be compared between the two consultation methods (telemedicine versus face-to-face consultation).
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time of medical care
Time Frame: through study completion, an average of 1 year
|
Comparison of time (minutes) of medical care between telemedicine and face-to-face consultation.
|
through study completion, an average of 1 year
|
|
Medical prescription
Time Frame: through study completion, an average of 1 year
|
Comparison of medical prescription after completion of the service between telemedicine and face-to-face consultation.
|
through study completion, an average of 1 year
|
|
Proposed destination after completion of the service
Time Frame: through study completion, an average of 1 year
|
Comparison of proposed destination (percentage of discharge or hospitalization) after completion of the service between telemedicine and face-to-face consultation.
|
through study completion, an average of 1 year
|
|
Rate of indication for complementary exams
Time Frame: through study completion, an average of 1 year
|
Comparison of rate (porcentage) of indication for complementary exams between telemedicine and face-to-face consultation.
|
through study completion, an average of 1 year
|
|
Types of requested exams
Time Frame: through study completion, an average of 1 year
|
Comparison of types of requested exams (porcentage) between telemedicine and face-to-face consultation.
|
through study completion, an average of 1 year
|
|
Guidelines follow-up
Time Frame: through study completion, an average of 1 year
|
Comparison of guidelines follow-up (porcentage) between telemedicine and face-to-face consultation.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 20, 2022
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
March 11, 2021
First Submitted That Met QC Criteria
March 16, 2021
First Posted (Actual)
March 17, 2021
Study Record Updates
Last Update Posted (Actual)
February 11, 2022
Last Update Submitted That Met QC Criteria
February 10, 2022
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 36793220300000071
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Infection
-
Christopher C. Thompson, MD, MScErbe Elektromedizin GmbHRecruitingHelicobacter Pylori Infection | H. Pylori Infection | Helicobacter Pylori | Helicobacter Pylori Gastrointestinal Tract Infection | H. Pylori Gastrointestinal DiseaseUnited States
-
QIAGEN Gaithersburg, IncCompletedGastrointestinal InfectionUnited Kingdom
-
West Virginia UniversityTerminatedSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Nanchang UniversityCompletedSurgical Site Infection | Gastrointestinal Surgery | Postoperative Gastrointestinal Dysfunction | MirabiliteChina
-
Damascus HospitalUNIPHARMA. Universal Pharmaceutical Industries; Ibn Alhaytham Pharma. Industries...UnknownHelicobacter Pylori Gastrointestinal Tract InfectionSyrian Arab Republic
-
Damascus HospitalWithdrawnHelicobacter Pylori Gastrointestinal Tract InfectionSyrian Arab Republic
-
University of Buenos AiresRecruitingH Pylori Infection | H.Pylori Gastrointestinal DiseaseArgentina
-
Temple UniversityPennsylvania Department of HealthCompletedRespiratory Viral Infection | Gastrointestinal InfectionUnited States
-
Bradley ConnorEnrolling by invitationGastrointestinal Disease | Small Intestinal Bacterial Overgrowth | Gastrointestinal InfectionUnited States
-
TakedaCompleted
Clinical Trials on Face-to-face Consultation
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFunctional Dyspepsia | Irritable Bowel Syndrome (IBS) | Abdominal Migraine | Functional Abdominal Pain DisordersNetherlands
-
OncoHelp AssociationNot yet recruiting
-
NHS LothianUniversity of EdinburghTerminatedAbortion in First Trimester | Abortion EarlyUnited Kingdom
-
Hospital Israelita Albert EinsteinCompletedRespiratory Tract InfectionsBrazil
-
University of Sao Paulo General HospitalCompleted
-
The Hong Kong Polytechnic UniversityTuen Mun HospitalCompletedDiabetes MellitusHong Kong
-
The Hong Kong Polytechnic UniversityThe Queen Elizabeth HospitalRecruiting
-
Radboud University Medical CenterUnknown
-
Gorm GreisenCompletedNewborn | Vaccination | Parental Consent
-
Insel Gruppe AG, University Hospital BernCompletedAcne VulgarisSwitzerland